bioMérieux, a pioneer in the fight against infectious diseases
“As a major global player in the diagnosis of infectious diseases, bioMérieux develops diagnostic tests and educational tools which play a highly instrumental part in the fight against antimicrobial resistance.
Building on more than 50 years of commitment to serving global public health and its leadership position in microbiology, bioMérieux has long made the fight against antimicrobial resistance one of its core priorities.
Chairman and CEO of bioMérieux
Born in Lyon, France, in 1870, Marcel Mérieux was a personal assistant to Louis Pasteur, who was the first to develop a vaccination method. He founded the Institut Mérieux back in 1897 and, inspired by his mentor, never forgot to focus on both veterinary and human medicine together. In 1935, approximately 40 people were employed by the Institut Mérieux, producing some 15,000 doses of tuberculin and 450,000 doses of immune sera and veterinary vaccines per year. Later, Marcel Mérieux’s son, Dr Charles Mérieux, would often be quoted as saying “There are no borders between human and veterinary medicine”.
In 1963, Alain Mérieux — Marcel Mérieux’s grandson — founded bioMérieux with the commitment to serve public health worldwide through in vitro diagnostics. Since its origins, bioMérieux has researched, developed and brought to market high medical value diagnostic tools and solutions to identify infections as quickly as possible, using current state-of-the art science and technology. From its very creation, in 1963, bioMérieux offered a range of products for laboratory testing, covering the fields of bacteriology, biochemistry, coagulation and virology.
The introduction of automation in the clinical laboratories during the 1970s was a major milestone for the diagnostics industry, heralding the start of a revolution in the laboratory’s role and its effect on medical practice. However, labs still had to group samples in order to run their instruments at full capacity. It was in the 1980s that the possibility of individual tests began to emerge. The acquisitions of API Systems in 1987 and Vitek Systems in 1988 were turning points in bioMérieux’s history. VIDAS® would become the Company’s flagship product, enabling it to make a spectacular entry on the automated immunoassays clinical market in 1991, and then in the industrial microbiology sector.
By the end of the 20th century, automation had been extended to every area of in vitro diagnostics, which is now on course for further change with the advent of new technologies. Decisional algorithms to process and interpret data, digital imaging, mass spectrometry and telemedicine are bringing about major changes in the practice of medicine and the organization of healthcare. These are the signs of an underlying trend: the convergence of automation, information technology and the life sciences.
Today, bioMérieux is a publicly-listed family-run company that remains strongly attached to its roots. Following the Mérieux family’s seminal commitment to serving human and animal health worldwide, both aspects have always been handled within the single concept of “One Health”. In the field of antimicrobial resistance, such a holistic approach is especially important, and bioMérieux’s product and service offer includes the characterization of microbial flora, detection of specific pathogens, antibiotic resistance profiling, as well as analysis of food, drug, water and air samples in the clinical, veterinary and food sectors.
Beyond its core business of product development, bioMérieux is also a long-standing international advocate for awareness-raising activities related to antibiotic resistance. It has produced a wide array of educational material, increased its sponsorship for scientific studies and organizations, and continues to communicate actively about the global antibiotic resistance threat.
As a pioneer of in vitro diagnostics and a global leader in microbiology, bioMérieux offers a wide array of solutions for the implementation of WHO’s Global Action Plan for Antimicrobial Resistance.
bioMérieux has been selected as a supplier in a tender process by the Fleming Fund, a £265 million UK aid investment to tackle AMR (antimicrobial resistance) in low- and middle-income countries, in Africa and Asia Pacific. The Company was chosen by the Fleming Fund due to the outstanding performance of its diagnostic solutions, its organizational capacity in the targeted countries and its extensive expertise in training healthcare professionals in microbiology and AMR.
bioMérieux will be locally active in 18 out of the 24 countries taking part in the programme, with the aim of improving access to diagnostics to curb AMR. In each of these countries, over the next three years, the Company will equip one reference clinical laboratory and one veterinary laboratory with the VITEK® MS and VITEK® 2 systems for pathogen identification and susceptibility testing, and with MYLA® software for data processing.
> Read the Press Release
bioMérieux and the Fleming Fund: working together to tackle antimicrobial resistance
The diagnostic solutions developed by bioMérieux are well suited for answering the needs of human and veterinarian medicine, those of food safety and of any industry which relies on the effective control of microbial pathogens (for instance pharmaceutical, cosmetic and biotechnology companies). bioMérieux has built a unique expertise in microbial detection, enumeration, identification and antibiotic susceptibility testing. The company is continually investing in research and development and has established strategic partnerships to develop innovative solutions. Its long-term commitment is to combat the persistent threat from infectious diseases and provide new weapons against emerging resistance.
bioMérieux is leveraging its commitment and history of fighting infectious diseases to provide solutions and services to help curb antibiotic resistance worldwide. No other healthcare solutions company brings the same level of expertise and innovation to address this problem, spanning the human, veterinary, environmental and food sectors.
As a pioneer in the development of antibiotic resistance detection and susceptibility testing, bioMérieux provides a number of diagnostic solutions to guide clinicians and support them in determining the most effective treatment. With speed and precision, bioMérieux’s tests identify the pathogen responsible for the infection and the organism’s susceptibility to antibiotics, thereby indicating the antibiotic agents best suited to treat the infection. They help make it possible to provide targeted, adjusted and specific therapies – only when necessary – often avoiding the administration of broad-spectrum antibiotics.
bioMérieux provides solutions to facilitate the preparation and analysis of biological samples, detect and quantify disease-causing agents, evaluate their susceptibility to antibiotics, and monitor antibiotic drug resistance trends over time. This is key for determining the sources of disease and contamination, improving human and animal health, and ensuring agri-food and medical product safety. (ref.01)Antimicrobial resistance WHO Fact sheet N°194, updated April 2015.